Following two (2) years of sluggish revenue performance, GlaxoSmithKline Consumer Plc (GLAXOSMITH) ended 2022FY with double digit topline expansion, anchored on the recovery of its pharmaceutical segment. Revenue from the pharmaceutical segment (c.66% of revenue surged 10.50% YoY to NGN16.75bn (vs NGN15.16bn in 2021FY), anchored on higher prices of prescription medicine as well as higher sales volume in the segment.
You May Also Like
Earnings Update – FBNH 2022FY. Deteriorating Capital Adequacy Raises Concerns
- June 19, 2023
FBN Holdings Plc. (FBNH) published its long-anticipated financial scorecard for 2022FY and Q1:2023. In 2022FY, the group recorded…
Earnings Update | ZENITHBANK | H1:2020
- September 13, 2020
Zenith Bank Plc (ZENITHBANK)’s interest income rebounded strongly (+11.40% YoY) in Q2:2020, after suffering a 6.65% YoY decline…
Earnings Update | FIDSON | 2020FY
- April 12, 2021
Fidson Healthcare Plc. turned a corner in 2020FY after a revenue contraction experienced in 2019FY on the back…
Earnings Update | MTNN | 2021FY
- February 18, 2022
Despite the challenging regulatory environment faced during early part of 2021, MTNN delivered strong results, with revenue climbing…
Earnings Update- UACN- H2:2021
- August 13, 2021
UACN delivered a momentous topline performance in the just concluded financial period. The company recorded strong double-digit growth…
Earnings Update | DANGCEM | Q1:2020
- June 5, 2020
Dangote Cement Plc. (DANGCEM) in Q1:2020 recorded an improved topline performance over the corresponding period of 2019. Group…